Employees: 613
Size Hangzhou Biotest Biotech (688767.SS) is a China Health Care company (Medical Specialties) with a market value of $878M, the 2414th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥36.72 on 18 Nov 2026.
Performance Over six months the shares fell 11.7%, against -15.1% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue fell 4.5% over the last twelve months (peer median +7.3%); the operating margin is 3.2% (peer median 9.4%).
Valuation It trades at 37.0× forward earnings against a peer median of 24.1× (5th most expensive of 15).
Capital Return on invested capital runs 4.5 points below its cost of capital (7.0% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥452M | CN¥445M | CN¥555M | CN¥439M | CN¥1.88B |
| Revenue growth | — | -20% | +27% | -77% | — |
| Gross profit | CN¥221M | CN¥192M | CN¥283M | CN¥208M | CN¥993M |
| EBITDA | n/a | CN¥35.5M | CN¥135M | CN¥33.1M | CN¥776M |
| Net income | CN¥10.3M | CN¥49.3M | CN¥170M | CN¥107M | CN¥774M |
| Free cash flow | -CN¥43.3M | -CN¥16.4M | -CN¥108M | CN¥78.8M | CN¥539M |
| Capital expenditure | CN¥139M | CN¥130M | CN¥245M | CN¥56.4M | CN¥179M |
| Total debt | CN¥100M | CN¥18.6M | CN¥440,516 | CN¥3.04M | CN¥7.64M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688767.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.6% | -6.8% | 11th highest of 21 |
| 6-month return | -11.7% | -15.1% | 9th highest of 21 |
| Distance from 52-week high | -28.0% | -43.3% | 6th highest of 21 |
| Revenue growth (TTM) | -4.5% | +7.3% | 3rd lowest of 21 |
| Operating margin | 3.2% | 9.4% | 4th lowest of 21 |
| Forward P/E | 37.0× | 24.1× | 5th most expensive of 15 |
| ROIC minus cost of capital | -4.5 pp | +1.5 pp | 6th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hangzhou Biotest Biotech 688767.SS | China | $878M | -12% | -4% | 3% | 37.0× | n/a | n/a |
| Xiangyu Medical 688626.SS | China | $877M | -38% | 0% | 4% | 56.2× | n/a | n/a |
| Shenzhen YHLO Biotech 688575.SS | China | $882M | -16% | +3% | 12% | 30.7× | 2.0% | +12.7% |
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | n/a | n/a | n/a |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $888M | -12% | +17% | 18% | 26.2× | 19.3% | +23.3% |
| Beijing SDL Technology 002658.SZ | China | $864M | -34% | -13% | 9% | 22.4× | 16.8% | +2.9% |
| Bioventus BVS | United States | $895M | -3% | +4% | 10% | 13.0× | 7.5% | +12.1% |
| HOB Biotech 688656.SS | China | $858M | -33% | +6% | 7% | 166.9× | 37.6% | +12.4% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $858M | -25% | +4% | 30% | n/a | 11.1% | +4.6% |
| Artivion AORT | United States | $905M | -18% | +14% | 5% | 383.6× | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $907M | -12% | +41% | 6% | 70.5× | n/a | n/a |
| Modern Dental 3600.HK | Hong Kong | $844M | +24% | +12% | 22% | 8.5× | -7.1% | +11.3% |
| Cisen Pharmaceutical 603367.SS | China | $843M | -15% | -6% | 8% | 7.9× | -14.6% | -1.3% |
| Cofoe Medical Technology 1187.HK | Hong Kong | $836M | -11% | +40% | 10% | 13.1× | -6.4% | +6.6% |
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | n/a | n/a | n/a |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | n/a | 35.6% | +17.1% |
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | n/a | 32.6% | +21.0% |
| Menicon 7780.T | Japan | $944M | +26% | +6% | 9% | 20.9× | n/a | n/a |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | n/a | n/a | n/a |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 25.8× | 2.7% | +20.9% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 20.7× | 20.0% | +21.4% |